Posting of Circular

4D PHARMA plc

(the "Company" or "4D")

Posting of Circular

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutic products confirms that, following its announcements of 18 February 2020, it has today posted a circular to Shareholders setting out details of its proposed Subscription and Placing to raise £22 million (before expenses) (the "Circular"). Accompanying the Circular is a notice of general meeting to be held in connection with the Subscription and Placing, to be held at its headquarters at 9 Bond Court, Leeds, England, LS1 2JZ at 10 a.m. on 9 March 2020.

A copy of the Circular will shortly be available to download from the Company's website at www.4dpharma.com.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.

About 4D PHARMA

Founded in February 2014, 4D is a world leader in the development of LBPs, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies LBPs based on a deep understanding of function and mechanism. 

4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical studies in progress, namely a Phase II clinical study of BLAUTIX® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration and option to license agreement with MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA), to discover and develop LBPs for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

About MRx0518

MRx0518, a product of 4D's discovery platform MicroRx®, is a single strain LBP in development for the treatment of cancer. It is delivered as an oral capsule and stimulates the body's immune system, directing it to produce cytokines and immune cells that are known to attack tumours.

It is currently being evaluated in three clinical trials in cancer patients. MRx0518-I-001 is a neoadjuvant monotherapy study in a variety of solid tumours and is being conducted at Imperial College (London, UK). MRx0518-I-002 is in combination with KEYTRUDA® (pembrolizumab) in collaboration with MSD. MRx0518-I-003 is a study in combination with radiotherapy in patients ,with resectable pancreatic cancer.